vTv Therapeutics Inc. (VTVT)
Health Care · Diabetes therapeutics / endocrinology drugs · NASDAQ
A late-stage biopharmaceutical company developing cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials for type 1 diabetes, with FDA Breakthrough Therapy designation.
What vTv Therapeutics Inc. does
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's lead program is cadisegliatin (TTP399), a novel small-molecule liver-selective glucokinase activator currently in Phase 3 clinical trials as an adjunctive therapy to insulin for type 1 diabetes, which received FDA Breakthrough Therapy designation in 2021. The company is advancing clinical development through the CATT1 Phase 3 trial and expanding to a Phase 2 study in type 2 diabetes patients in partnership with G42 Investments.
Themes: Type 1 diabetes treatment, Type 2 diabetes treatment, Glucokinase activators, Metabolic disease, Hypoglycemia reduction, Inflammatory disease
Fundamentals
- Price$33.57 as of 2026-08-26 close
- Market cap$125M as of 2026-08-27
- 1-year return+112.6% 2025-08-26 close $15.79 → 2026-08-26 close $33.57
- P/E55.59 as of 2026-08-27
- Net margin+65.5% as of 2026-08-27
- ROE+4.0% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Beta0.20 as of 2026-08-27
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How VTVT compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-27
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-27
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-27
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-27
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How vTv Therapeutics Inc. looks technically
VTv Therapeutics Inc. (VTVT) is trading 1.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day low about 9 trading days ago. It is 23.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.9% below its 200-day average, the long-term trend line — a long-term downtrend | -1.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $33.34 | $33.34 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $34.24 | $34.24 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 28.7579. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 16 trading days ago — a "death cross", a bearish long-term signal | 16 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($28.76 to $36.52) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 62.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $44.00 | $44.00 |
|---|---|---|
| From the 52-week high | it is 23.7% below its 52-week high (its highest price of the past year) | -23.7% |
| Above the 52-week low | it is 112.6% above its 52-week low (its lowest price of the past year) | +112.6% |
| Below the 52-week high | it is 23.7% below its highest point of the past year | 23.7% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $560.00 (set on 2015-07-30) | $560.00 |
| Given back of the 52-week move | over the past year its closes ranged ($15.79 to $42.72), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.21 to $26.08. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.0% |
| From the all-time high | it is 94.0% below its all-time high | -94.0% |
| Nearest price level | it is trading 0.9% above a support level at $33.26 — a price it turned at four times since 2025-11-11, most recently on 2026-06-26. Since 2024-08-26 it has 12 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $7.38 (set on 2024-01-26) | $7.38 |
| Above the all-time low | it is 354.9% above its all-time low | +354.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.85 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.85 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $30.23 and $35.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $30.23 – $32.87 – $35.51 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (2.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.30× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-26 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 5 sessions ago and has not traded back through the level it left behind at 31.48 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.6% gap down opened on 2026-08-20 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.3 percentage points (the stock gained 6.0% while the market gained 3.8%) | +2.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.8 percentage points (the stock gained 1.2% while the market gained 2.1%) | -0.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.8 percentage points (the stock lost 14.6% while the market gained 11.1%) | -25.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 93.9 percentage points (the stock gained 112.6% while the market gained 18.7%) | +93.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-20 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 2.0% of the share price, which is taken to mean a barrier that gives way easily. | -0.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $34.65 — a volume-weighted average of daily closes over 162 sessions, not a true tick-by-tick VWAP. | -3.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $33.29 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +0.8% |
Price levels it has turned at before
VTVT last closed at $33.57 on 2026-08-26. Since 2024-08-26 it has turned at 12 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $33.26 | Support | 0.9% below the last close | turned there four times · 2025-11-11 to 2026-06-26 |
| $35.05 | Resistance | 4.4% above the last close | turned there twice · 2026-04-10 to 2026-06-04 |
| $29.77 | Support | 11.3% below the last close | turned there three times · 2026-05-11 to 2026-07-28 |
| $28.78 | Support | 14.3% below the last close | turned there three times · 2026-02-06 to 2026-08-14 |
| $38.63 | Resistance | 15.1% above the last close | turned there twice · 2026-05-14 to 2026-06-30 |
| $41.51 | Resistance | 23.6% above the last close | turned there twice · 2026-02-24 to 2026-04-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $28.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 4 trading days, since 2026-08-21.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$53.83 range $42.00 – $67.00; median $56.00
Analyst estimates, as of 2026-08-26. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VTVT
- Consensus EPS estimate-$1.16 next reporting period, as of 2026-08-26
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risks: cadisegliatin previously faced a clinical hold from July 2024 to March 2025 due to radiochromatographic signal concerns in the ADME study, which could recur and delay or halt development programs.","Regulatory and approval risk: the company depends heavily on the Phase 3 CATT1 trial and future registrational studies for cadisegliatin approval; failure to meet endpoints or adverse safety signals could prevent market authorization.","Funding dependency: the company's operations depend on securing additional capital for clinical trials and development; market conditions or investor sentiment changes could limit funding availability."]
What changed in the latest 10-Q
AI-assisted comparison of VTVT's 10-Q filed 2026-05-13 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- In January 2026, the Company entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. providing global rights to HPP737 for $20.0 million upfront plus up to $115.0 million in milestone payments and mid to upper single digit royalties (filed 2026-05-13)
- Type 1 Diabetes Index estimated 1.5 million individuals live with T1D in the United States as of 2026 (filed 2026-05-13)
- Approximately 75% of Americans living with T1D not achieving HbA1c <7% target (filed 2026-05-13)
- FDA approval of teplizumab to delay onset of Stage 3 T1D and donislecel islet cell therapy mentioned as existing treatments (filed 2026-05-13)
- Phase 1 mechanistic study demonstrated no increased risk of ketoacidosis with cadisegliatin during acute insulin withdrawal in patients with T1D (filed 2026-05-13)
- Company has completed eleven Phase 1 and three Phase 2 clinical trials of cadisegliatin totaling more than 500 patients (filed 2026-05-13)
- Removed:
- Statement that 'There have been no material developments since our last reporting period' (filed 2025-11-06)
- Detailed information about FDA clinical hold issued July 26, 2024 and its removal on March 14, 2025 (filed 2025-11-06)
- Protocol amendment details shortening CATT1 study from 12 months to 6 months (filed 2025-11-06)
- Expectation of CATT1 top-line data in second half of 2026 (filed 2025-11-06)
- June 2025 food effect study in healthy volunteers to assess pharmacokinetics of cadisegliatin (filed 2025-11-06)
- Statement about further registrational studies for cadisegliatin expected to start in 2027 (filed 2025-11-06)
- Reference to G42 Investments AI Holding RSC Ltd. partnership and Phase 2 trial in Middle East for type 2 diabetes expected in fourth quarter 2025 (filed 2025-11-06)
- Reworded:
- Moved FDA Breakthrough Therapy designation and cadisegliatin mechanism description earlier in the section structure; now integrated into Company Overview section rather than appearing in T1D program section (filed 2026-05-13 vs 2025-11-06)
- Added expanded context on Type 1 Diabetes disease burden including ADA Standard of Care 2026 reference and discussion of existing therapy limitations and safety risks (filed 2026-05-13)
- Glucokinase mechanism description reframed with emphasis on 'physiological glucose sensor' role in blood glucose control and hypoglycemia reduction (filed 2026-05-13)
- SimpliciT-1 trial description now explicitly labeled as 'multi-center, randomized, double-blind, adaptive trial' with additional methodology details (filed 2026-05-13 vs older 'adaptive study' language)
- Notes:
- Text appears truncated at end of newer filing ('initiated our CATT1 trial to assess the effect of cadisegliatin on reducing the frequency of'); comparison limited to available content
- Recent Developments section substantially reorganized between filings—older version states 'no material developments' while newer version details January 2026 Newsoara transaction and removes clinical program updates, suggesting different reporting periods
Risk Factors
- Added:
- Newer filing (2026-05-13) shows Revenue of $36,839 thousand for Q1 2026, compared to $0 in older filing's Q3 2025
- Newer filing includes cadisegliatin described as 'currently in a Phase 3 trial' and 'potential first-in-class oral liver-selective glucokinase activator'
- Newer filing shows Operating income of $23,263 thousand for Q1 2026 versus operating loss in older filing
- Newer filing shows Net income of $24,134 thousand attributable to vTv Therapeutics Inc. for Q1 2026
- Newer filing shows Cash and cash equivalents of $98,086 thousand at March 31, 2026
- Newer filing shows Contract liabilities decreased to $1,830 thousand at March 31, 2026 from $18,669 thousand at December 31, 2025
- Newer filing shows Diluted EPS of $1.65 for Q1 2026
- Newer filing shows Basic EPS of $1.94 for Q1 2026
- Removed:
- Older filing (2025-11-06) shows Revenue of $0 for Q3 2025 and nine months ended September 30, 2025; removed in newer filing
- Older filing shows Operating loss of $10,699 thousand for Q3 2025; not applicable to newer Q1 2026 period
- Older filing shows Net loss of $8,698 thousand attributable to vTv Therapeutics Inc. for Q3 2025
- Older filing shows Property and equipment, net of $14 thousand and Operating lease right-of-use assets of $24 thousand at September 30, 2025; not present in newer balance sheet
- Older filing shows Current portion of notes payable of $328 thousand; not shown in newer filing
- Older filing shows Noncontrolling interest in balance sheet and changes in stockholders' equity; eliminated in newer filing
- Reworded:
- Risk Factors item numbering changed from page 30 (older) to page 26 (newer)
- Statement of Changes title changed from 'Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit)' in older filing to 'Statement of Changes in Stockholders' Equity' in newer filing
- Business description in newer filing emphasizes cadisegliatin being 'investigated as an adjunctive therapy to insulin for the treatment of type 1 diabetes,' whereas older filing does not include this specific indication detail in the excerpt provided
- Notes:
- The two filings cover different periods (Q1 2026 versus Q3 2025/nine months 2025) and are not directly comparable on a quarterly basis
- The newer filing is a 10-Q for period ended March 31, 2026; the older filing is a 10-Q for period ended September 30, 2025
- Changes in financial metrics reflect different reporting periods and may reflect operational changes, not just filing updates
- The text of the older filing appears truncated at the end of the Notes section, which may affect completeness of the comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for VTVT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding VTVT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 283,659
- Reported value $11,249,916
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VTVT had 165,792 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for VTVT because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 165,792
- Prior settlement (shares) 172,198
- Reported change -3.72%
- Days to cover (reported) 1.48
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VTVT vs…
Frequently asked questions
What does vTv Therapeutics Inc. (VTVT) do?
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's lead program is cadisegliatin (TTP399), a novel small-molecule liver-selective glucokinase activator currently in Phase 3 clinical trials as an adjunctive therapy to insulin for type 1 diabetes, which received FDA Breakthrough Therapy designation in 2021.
What sector is vTv Therapeutics Inc. (VTVT) in?
vTv Therapeutics Inc. (VTVT) is classified in the Health Care sector. Its industry is Diabetes therapeutics / endocrinology drugs. It trades on NASDAQ.
Who are vTv Therapeutics Inc.'s (VTVT) competitors?
Notable peers of vTv Therapeutics Inc. (VTVT) include Eli Lilly, Novo Nordisk, Sanofi, Vertex Pharmaceuticals and MannKind. This peer set is informational only — not financial advice.
Is vTv Therapeutics Inc. (VTVT) overbought or oversold right now?
vTv Therapeutics Inc. (VTVT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VTVT come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.